Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Posted on by

JINAN, China, Oct. 25, 2023 /PRNewswire/ — On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.